DDInter401 DDInter1652
Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Clobazam {u} (Compound) resembles {v} (Compound) Loxapine
Clobazam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Clobazam {u} (Compound) treats {v} (Disease) epilepsy syndrome
Clobazam {u} (Compound) binds {v} (Gene) CYP2C18
Clobazam {u} (Compound) is included by {v} (Pharmacologic Class) Benzodiazepines
Clobazam {u} (Compound) causes {v} (Side Effect) Abnormal behaviour
Clobazam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dyphylline
Clobazam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flumazenil
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Clobazam (Compound) resembles Loxapine (Compound)
Clobazam (Compound) resembles Flunitrazepam (Compound)
Clobazam (Compound) treats epilepsy syndrome (Disease)
Clobazam (Compound) binds CYP2C18 (Gene)
Clobazam (Compound) is included by Benzodiazepines (Pharmacologic Class)
Clobazam (Compound) causes Abnormal behaviour (Side Effect)
Clobazam may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Clobazam may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Flumazenil
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin